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ABSTRACT 
Objectives: To evaluate the incidence of metabolic syndrome in Turkish adolescents with different phenotypes of polycystic 
ovary syndrome (PCOS).
Material and methods: This cross-sectional study was performed on the Youth Center clinic of a tertiary referral hospi-
tal in Turkey. Adolescents with PCOS (n = 144) were classified into four phenotype groups according to the presence of 
oligo/anovulation (O), hyperandrogenism (H), and polycystic ovarian morphology (P) as follows: Phenotype A (O + H + P), 
Phenotype B (H + O), Phenotype C (H + P), Phenotype D (O + P). The adolescents gave early follicular phase blood samples 
for endocrine and metabolic tests. The incidence and the presence of parameters of metabolic syndrome were assessed 
among the four groups.
Results: In total, 54.9% of the adolescents with PCOS were overweight and 25.7% had metabolic syndrome. The incidence 
of metabolic syndrome in Phenotypes A-D were as follows: 39.5%, 20.5%, 26.5%, and 15.2%, respectively. Although body 
mass index was higher in the Phenotype A group, insulin resistance was similar in all of the phenotype groups. The most 
common dyslipidemia was low HDL-C levels and this was present in more than half of the adolescents with PCOS. Both body 
mass index and total testosterone levels were significantly higher in adolescents with metabolic syndrome in comparison 
to those without metabolic syndrome.
Conclusions: Although low HDL-C levels and insulin resistance are common PCOS findings in adolescents, the metabolic 
profile seems to be worse in Phenotype A than the other phenotypes. Therefore, screening programs should evaluate 
patients based on the known risk factors and phenotypes for adolescents with PCOS.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most frequent 
endocrine disorder in reproductive-aged women. Although 
the exact cause is unknown, current evidence suggests that 
PCOS is a complex genetic disorder, and excess androgen 
produced by ovaries during puberty is supposed to be the 
initiating factor [1, 2]. PCOS is a clinically and biochemi-
cally heterogeneous disease and girls with PCOS are at 
an increased risk for MS, diabetes mellitus and a decreased 
cardiovascular event-free survival in advancing age [3]. MS 
is a combination of multiple risk factors that arise from 
insulin resistance accompanying abnormal adipose deposi-
tion and function. Women with MS are at increased risk for 
coronary heart disease, diabetes, fatty liver and several can-
cers. Although this syndrome affects women from infancy to 
menopause the diagnostic criteria for diagnosis if PCOS in 
adolescents is still highly controversial as the physiological 
changes in adolescence and the hormonal inbalance dur-
ing maturation of the hypotalamo-hypophysis-ovarian axis 
in adolescents might mimic some symptoms of PCOS [4]. 
In 2012, PCOS Consensus Workshop group stated that 
only adolescents that meet the three Rotterdam criteria 
should be diagnosed with PCOS [5]. According to this de-
scription, only phenotype A can be considered as PCOS 
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in adolescents. However, there is great heterogeneity in 
ovarian morphology among adolescents, and the ultrasono-
graphic diagnosis of polycystic appearance of the ovaries 
before the age of 17 is inaccurate [6]. Moreover, other studies 
suggested that ovarian hyperandrogenism might not be-
come prominent during early adolescence, and adolescents 
who had only anovulation and polycystic ovaries might 
also be diagnosed with PCOS in the follow-up period [7, 
8]. Therefore, it is not appropriate to exclude the diagnosis 
of PCOS in the absence of hyperandrogenism or polycystic 
ovarian morphology in adolescents. In adults, PCOS is cur-
rently diagnosed using the presence of two out of three 
Rotterdam criteria, and four reproductive phenotypes have 
been defined. Currently, the issue of the selection of the ap-
propriate criteria for the diagnosis of PCOS in adolescents 
is still debatable [9]. The American College of Obstetricians 
and Gynecologists (ACOG) and the Androgen Excess Society 
(AES) guidelines state that hyperandrogenism is an essential 
criterion for the diagnosis of PCOS [10–12].
In this study, in order not to overlook the diagnosis of 
PCOS, we used Rotterdam criteria for diagnosing PCOS in 
adolescents and analyzed the results for each one of the 
4 phenotypes.
OBJECTIVES
The incidence of MS has been reported as to be as 
high as 37% in adolescents with PCOS [13] and AES cur-
rently recommends a cardio-metabolic assessment for all 
adolescents with PCOS [10]. In order to decrease the future 
cardiovascular mortality, it is crucial to accurately identify 
the PCOS phenotypes that have and increased risk for MS 
in adolescents. It is known that the adolescents who do not 
currently fulfill the three Rotterdam criteria might also be 
diagnosed as PCOS in the following years, therefore, they 
might also be a candidate for metabolic syndrome. The 
hypothesis of the study is Turkish adolescents who met any 
two of three Rotterdam criteria also has a similar incidence 
of MS and metabolic risk profile with those who met all 
three Rotterdam criteria.
MATERIAL AND METHODS
Study participants
This cross-sectional study was conducted at the Youth 
Center Clinic of Etlik Zubeyde Hanim Women’s Health Train-
ing and Research Hospital, between January 1, 2014 and 
December 31, 2014. The hospital’s Institutional Review 
Board approved the study. Written informed consents were 
obtained from all participants and/or their parents before 
their participation. Before recruitment to the study, all ado-
lescents were evaluated by a reproductive endocrinology 
specialist and other etiologies that cause hyperandrogenism 
were ruled out. The adolescents who were diagnosed to 
have PCOS were enrolled into the study. A total of 144 con-
secutive adolescents with newly diagnosed PCOS who had 
a signed written consent were included. All were at least 
two years post-menarche during the initial assessment of 
the study. 
 The diagnosis of PCOS was based on the presence of 
two out of three Rotterdam criteria that were proposed 
in 2003 after exclusion of the other medical conditions 
that cause hyperandrogenism. Those criteria are: (1) clinical 
and/or biochemical hyperandrogenism; (2) oligomenorrhea 
persistent 2 years after menarche, < 6 menstrual cycles per 
year, and menstrual cycles intervals > 35 days; (3) presence 
of ultrasonographic polycystic ovary (PCO) appearance. 
Clinical hyperandrogenism is defined as the presence of 
hirsutism, as determined by a Ferriman Gallwey score of 
8 or higher. Presence of acne and alopecia without hirsutism 
was not enough to fulfill the criterion for clinical hyperan-
drogenism. Biochemical hyperandrogenism is defined as 
increased total testosterone (> 0.73 ng/mL; upper limits 
of the laboratory). PCO is defined as the presence of at 
least 12 follicles measuring 2–9 mm, or an ovarian volume 
greater than 10 cm3. The exclusion criteria were: pregnancy, 
diabetes mellitus, thyroid disorder, hyperprolactinemia, con-
genital adrenal hyperplasia or an androgen-secreting tumor, 
known cardiovascular disease; smoking and/or substance 
abuse; or drugs use that affect carbohydrate and fat metabo-
lism, such as oral contraceptives and metformin.
During the study period, all adolescents with PCOS were 
examined by specialists and classified into four phenotypes: 
Phenotype A: hyperandrogenism (HA) + oligoanovulation 
(OA) + PCO; Phenotype B: hyperandrogenism + oligoan- 
ovulation; Phenotype C: hyperandrogenism + PCO; and 
Phenotype D: oligoanovulation + PCO. 
The demographic characteristics, the medical history 
and hirsutism score of all the participants were recorded. 
A complete physical examination for anthropometric meas-
urements was followed by blood pressure measurement.
Study protocol
All participants underwent anthropometric measure-
ments, such as weight, height, waist, and hip circumference. 
Body mass index (BMI) was also calculated as the formula 
of weight divided by the square of height. The participants’ 
blood pressure was also measured. One of the researchers 
(KZA) performed an ultrasonographic examination (General 
Electric LOGIQ A5, USA) on all participants to investigate the 
presence of polycystic ovarian morphology and to exclude 
other gynecologic pathologies. 
Fasting venous blood was taken in the early follicu-
lar phase of menstruation and used for biochemical and 
hormonal analysis. The laboratory investigations included 
measurement of the lipid profile — triglycerides (TG), cho-
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lesterol, high-density lipoprotein (HDL), low-density lipopro-
tein (LDL) — glucose metabolism (fasting glucose, fasting 
insulin) and hormone levels for follicle stimulating hormone 
(FSH), luteinizing hormone (LH), estradiol (E2), testosterone 
(T), dehydroepiandrostenedione sulphate (DHEA-S), and 
17 hydroxyprogesterone (17-OH-P). Insulin resistance was 
measured using a homeostasis model assessment score 
(HOMA-IR) that was calculated as fasting insulin × fasting 
glucose/22.5. 
Fasting glucose was measured with a Roche module 
using the glucose oxidase method; fasting insulin was meas-
ured with the Siemens Immulite 2500 (Siemens, USA) ana-
lyzer using the immune chemiluminescence method. Assays 
for FSH, LH, E2, DHEA-S, and 17-OH-P were performed using 
the Roche E170 hormone auto-analyzer (Roche Diagnostics, 
USA) with electro chemiluminescence. Cholesterol and TG 
levels were measured using the Roche P800 auto-analyzer 
(Roche Diagnostics) with the cholesterol esterase and lipo-
protein lipase method, respectively. LDL and HDL assays 
were performed using the Roche P800 auto-analyzer with 
LDL-cholesterol 2nd generation analysis kit and the HDL-cho-
lesterol 3rd generation analysis kit (Roche Diagnostics).
The International Diabetes Federation (IDF) criteria for 
MS in children and adolescents was used for the diagnosis 
of MS [11]. Central obesity, defined as a waist circumfer-
ence ≥ 80 cm, is the essential component of this definition. 
The presence of two of the following four criteria was re-
quired: (1) TG ≥ 150 mg/dL; (2) HDL < 50 mg/dL; (3) fasting 
plasma glucose ≥100 mg/dL; and (4) systolic blood pres-
sure ≥ 130 mm Hg, diastolic blood pressure ≥ 85 mm Hg.
Statistical analysis
Data analysis was performed using IBM SPSS Statistics 
for Windows, Version 21.0. (IBM Corp., Armonk. NY). Compli-
ance of the continuous variables with normal distribution 
was examined using the Kolmogorov Smirnov test. The 
descriptive statistics were shown as median values (inter-
quartile range) for the non-normally distributed data and 
as median ± standard deviation values for the normally 
distributed data. The significance of the differences between 
the mean and median values of the four groups was evalu-
ated using the Student’s t test and the Mann Whitney U test, 
respectively. The nominal variables were analyzed using the 
Chi-square test. The Mann Whitney U test was performed in 
order to test the significance using Bonferroni correction to 
adjust for multiple comparisons. Unless otherwise specified, 
p < 0.05 is accepted as statistically significant. 
RESULTS
Of the 144 participants, 38 (26.3%) were Phenotype A, 
39 (27.1%) were Phenotype B, 34 (23.6%) were Phenotype 
C, and 33 (22.9%) were Phenotype D (Tab. 1). The mean age 
of the entire cohort was 17.25 ± 1.22, and the ages of the 
adolescents in all four phenotypes were similar. Of all adoles-
cents, 110 (76.4%) had oligo-anovulation while 109 (75.7%) 
had hirsutism. The history of PCOS in their family was present 
in 62 (43.2%) adolescents. The incidence of family history 
of PCOS was significantly higher in the Phenotype A group 
compared to the other phenotypes (63.2% vs. 35.8%; 
p = 0.004) (Tab. 1).
The metabolic and hormonal characteristics of the ado-
lescents with PCOS phenotypes are shown in Table 2. BMI 
and waist circumference were significantly higher in the 
Phenotype A group compared to the other phenotypes 
(p = 0.006 and p = 0.036, respectively). Seventy-nine (54.9%) 
of the 144 participants in the cohort were overweight. As 
expected, the Ferriman Gallwey scores, the LH and testoster-
one levels were significantly higher in the hyperandrogen-
emic phenotypes (Phenotypes A, B, and C) compared to the 
normoandrogenemic Phenotype D (p < 0,001, p = 0,002 and 
p < 0,001, respectively). 
However, the fasting glucose, insulin, and HOMA-IR, 
were similar in all four of the PCOS phenotypes (p = 0,016, 
p = 0,427 and p = 0,122, respectively). In addition, no sig-
nificant differences in the lipid parameters, such as total 
cholesterol, LDL-C, HDL-C, and TG were observed among 
the four PCOS phenotypes (p = 0.11, p = 0.10, p = 0.29 and 
p = 0.12, respectively). The testosterone and LH levels were 
significantly lower in Phenotype D (OA + PCO) compared to 
Phenotype A Phenotype B and Phenotype C (p < 0,001 and 
Table 1. Demographic characteristics of the adolescents with 4 phenotypes of PCOS
Phenotype A
HA + AO + PCOS
Phenotype B
HA + AO
Phenotype C
HA + PCO
Phenotype D
AO + PCO
N 38 (26.3%) 39 (27.1%) 34 (23.6%) 33 (22.9%)
Age 17.45 ± 1.16 17.13 ± 1.26 17.18 ± 1.16 17.24 ± 1.16
Family history of PCOS 24 (63.2%) 15 (38.5%) 14 (41.2%) 9 (27.3%)
Oligo-anovulation + + – +
Hyperandrogenism + + + –
Polycystic ovaries + – + +
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p = 0,002, respectively). The presence of the metabolic syn-
drome parameters [11] for the four PCOS phenotypes are 
shown in Table 3. In the entire cohort 37 (25.7%) adolescents 
were diagnosed with MS according to IDF criteria. Although 
it did not reach to a statistical significance, the incidence 
of MS was highest (39.5%) in Phenotype A and lowest in 
Phenotype D (15.2%). 
Out of 144 participants l, seventy-nine (54.9%) were 
overweight and 116 (80.5%) had abdominal obesity. The 
incidence of being overweight and having abdominal obe-
sity were similar in four phenotypes (p = 0.10 and p = 0.85, 
respectively). Both systolic and diastolic blood pressures 
were also similar in all phenotypes (p = 0.26 and p = 0.19, 
respectively). High triglyceride levels (TG ≥ 150 mg/dL) were 
present in 38 (26.4 %) of all adolescents. Low HDL levels 
were also present in 122 (84.7%) of the adolescents and 
all four phenotypes had similar incidence of low HDL and 
elevated TG levels. 
The endocrinologic and metabolic characteristics of 
adolescents, with and without MS, were compared in Ta-
ble 4. The ages of the adolescents with and without MS were 
similar. However, mean BMI and median waist circumfer-
ence were significantly higher in the adolescents with MS 
(29.63 ± 3.26 vs. 24.46 ± 3.26; p < 0.001 and 88 (8) vs. 68 (15); 
p < 0.001, respectively). As expected, the insulin resistance 
evaluated with HOMA-IR levels were significantly higher in 
Table 2. Metabolic and hormonal characteristics of the patients with PCOS
Characteristics Phenotype A Phenotype B Phenotype C Phenotype D p value
BMI 27.16 ± 4.14 25.14 ± 3.87 24.98 ± 4.05 25.32 ± 4.14 p = 0.006a
WC [cm] 0.84 (0.08) 0.77 (0.14) 0.78 (0.15) 0.79 (0.10) p = 0.007b
Ferrimann-Gallwey score 10.0 (3.0) 9.0 (2.0) 9.0 (2.0) 3.0 (2.0) p < 0.001c
Fasting glucose [mg/dL] 90 (9.0) 87 (10.0) 86 (9.0) 88 (8.0) p = 0.016
Insulin [µIU/mL] 9.98 (2.32) 10.20 (2.08) 9.76 (2.10) 9.15 (3.08) p = 0.427
HOMA-IR 2.17 (0.77) 2.15 (0.84) 2.14 (0.60) 1.94 (0.68) p = 0.122
Testosterone [ng/mL] 0.8 (0.4) 0.8 (0.2) 0.7 (0.3) 0.6 (0.2) p < 0.001d
FSH [IU/L] 5.19 (2.12) 5.60 (2.12) 5.03 (2.59) 5.40 (1.87) p = 0.621
LH [IU/L] 9.88 (2.76) 10.55 (2.77) 9.16 (4.70) 8.33 (2.68) p = 0.002e
DHEAS [µg/dL] 221.0 (94.0) 201.5 (136.0) 171.5 (118.0) 174.5 (108.0) p = 0.42
17 OH Prog [ng/mL] 0.98 (0.18) 0.96 (0.25) 0.95 (0.20) 0.89 (0.34) p = 0.48
Cholesterol [mg/dL] 176.0 (42.0) 160 (39.0) 182.5 (45.0) 154.5 (39.0) p = 0.11
TG [mg/dL] 134.0 (74.0) 95.0 (28.0) 100.5 (57.0) 100.0 (35.0) p = 0.12
LDL [mg/dL] 87.5 (24.0) 88.0 (19.0) 90.0 (19.0) 78.0 (19.0) p = 0.10
HDL [mg/dL] 37.0 (9.0) 39.0 (10.0) 39.5 (11.0) 39.0 (7.0) p = 0.29
Abbreviations: aA vs. BCD, bA vs. BCD, cABC vs. D, dABC vs. D, eABC vs. D 
BMI — body mass index; WC — waist circumference; HOMA-IR — homeostatic model assessment-insulin resistance; FSH — follicle stimulating hormone; LH — luteinizing 
hormone; DHEAS — dehydroepiandrosterone sulphate; Prog — Progesteron; TG — triglyceride; LDL — low-density lipoprotein; HDL — high-density lipoprotein
Table 3. The incidence of the parameters of metabolic syndrome in four PCOS phenotypes (N, %)
Phenotype A Phenotype B Phenotype C Phenotype D p value
Overweight 27 (71.1%) 17 (43.6%) 17 (50.0%) 18 (54.5%) 0.10
Abdominal obesity 31 (81.6%) 30 (76.9%) 27 (79.4%) 28 (24.1%) 0.85
Hypertension 8 (21.1%) 4 (10.3%) 5 (14.7%) 2 (6.1%) 0.27
TG ≥ 150 [mg/dL] 17 (44.7%) 8 (20.5%) 8 (23.5%) 5 (15.2%) 0.023
HDL < 50 [mg/dL] 33 (86.9%) 31 (79.5%) 28 (82.4%) 30 (90.9%) 0.56
Glu ≥ 100 [mg/dL] 7 (18.4%) 2 (5.1%) 4 (11.8%) 1 (3.0%) 0.11
Systolic BP [mm Hg] 115.0 (10.0) 110.0 (10.0) 110 (10.0) 110 (10.0) p = 0.26
Diastolic BP [mm Hg] 73.7 (10.0) 71.3 (5.0) 72.6 (10.0) 69.7 (5.0) p = 0.19
Mets (IDF) 15 (39.5%) 8 (20.5%) 9 (26.5%) 5 (15.2%) 0.10
Abbreviations: TG —triglyceride; HDL — high-density lipoprotein; Glu — fasting plasma glucose; Mets (IDF) — metabolic syndrome diagnosed with International 
Diabetes Federation; BP — blood pressure
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the MS group compared to those without MS (2.56 (0.79) 
vs. 1.98 (0.58); p < 0.001). In concordance with the presence 
of insulin resistance, the lipid profile results were worse in 
the adolescents with MS compared to those without MS. The 
serum triglyceride levels were significantly higher (153 (12) 
vs. 92 (28); p < 0.001) and HDL levels were significantly lower 
(35 (9) vs. 40 (10); p < 0.001) in MS group compared to those 
without MS. The endocrine profiles were also compared 
between two groups, and adolescents with MS had higher 
the serum testosterone levels compared to those without 
MS (0.82 (0.3) vs. 0.7 (0.24); p = 0,004). The DHEA-S levels 
were similar in both groups (0.95).
DISCUSSION
Although many previous studies have investigated MS 
in adult women with PCOS, there is limited data concerning 
the incidence of MS in adolescents with PCOS [14–16]. In 
the present study, more than half of the adolescents were 
overweight and 25.7 % (37/144) were diagnosed with MS 
using IDF criteria. Although it was not statistically significant, 
the incidence of MS was highest in the adolescents with 
Phenotype A (39.5%) — the phenotype that meets all three 
Rotterdam criteria — and it was lowest in the normoandro-
genemic Phenotype D (15.2%). Rahmanpour investigated 
30 Iranian adolescents with PCOS and reported that 52% 
of them were overweight and 33.3% had MS [14]. Recently, 
Aydin et al. reported a 7.9% incidence of MS using Cook crite-
ria in 63 normal-weight Turkish adolescents with PCOS [16]. 
However, in one large study, the incidence of MS was re-
ported to be as 3.9 % in healthy Turkish adolescent girls [17]. 
When our study and former studies were taken into consid-
eration, we could conclude that, Turkish adolescents with 
PCOS have an approximately five-times increased risk for 
MS compared to healthy adolescents.
Although the pathogenesis of PCOS is unknown, there 
is an increasing evidence on that insulin resistance has 
a critical role on the steroidogenic dysregulation of PCOS. 
Suggesting the role of insulin on ovarian function, patients 
having severe insulin resistance due to presence of insulin 
receptor mutations are accompanied by PCOS [18]. In these 
cases, extreme hyperinsulinemia might stimulate the insulin 
like growth factor-1 (IGF-1) that results increased androgen 
production in ovarian thecal cells. Insulin also acts in con-
junction with LH to increase the androgen production in the 
ovary. According to our results, adolescents with four PCOS 
phenotypes had similar rates of insulin resistance, as evalu-
ated using HOMA-IR. This finding was in concordance with 
the results from previous studies [19, 20], and it confirms 
that insulin resistance is the common underlying feature 
of PCOS in adolescence.
Although the most probable link between PCOS and 
MS is insulin resistance and hyperinsulinism, the abdominal 
obesity also supposed to deteriorate the metabolic dysfunc-
tion in women with PCOS [21]. The insulin is a known me-
diator for the development of obesity. Insulin stimulate the 
formation of mature adipocytes from preadipocytes by the 
Table 4. Comparison of the endocrinologic and metabolic parameters in PCOS women with and without metabolic syndrome (n = 144)
Characteristics Women  without metabolic syndrome 
Women  
with metabolic syndrome p value
Age (years) 17.26 ± 1.22 17.21 ± 1.25 0.84
BMI [kg/m2] 24.46 ± 3.30 29.63 ± 3.26  < 0,001
WC [cm] 68.0 (15.0) 88.0 (8.0)  < 0,001
Metabolic characteristics
Fasting glucose [mg/dL] 87.0 (8.0) 94.0 (14.0)  < 0,001
Insulin [µIU/mL] 9.2 (2.61) 10.8 (2.08)  < 0,001
HOMA-IR 1.98 (0.58) 2.56 (0.79)  < 0,001
Cholesterol [mg/dL] 158.0 (36.0) 197.0 (21.0)  < 0,001
Triglyceride [mg/dL] 92.0 (28.0) 153.0 (12.0)  < 0,001
LDL [mg/dL] 80.0 (20.0) 92.5 (19.0) 0,003
HDL [mg/dL] 40.0 (10.0) 35.0 (9.0)  < 0,001
Endocrinological characteristics
Testosterone [ng/mL] 0.70 (0.24) 0.82 (0.35) 0,004
DHEA-S [ng/mL] 205.0 (135.0) 221.0 (117.0) 0.95
FSH [IU/L] 5.25 (2.10) 5.35 (2.27) 0.59
LH [IU/L] 9.37 (3.87) 10.11 (3.18) 0.21
Abbreviations: BMI — body mass index; WC — waist circumference; HOMA-IR — homeostatic model assessment-insulin resistance; LDL — low-density lipoprotein;  
HDL — high-density lipoprotein; DHEA-S — dehydroepiandrosterone sulphate; FSH — follicle stimulating hormone; LH — luteinizing hormone
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action a common transcription factor named Kruppel-like 
factor 15 (KLF-15). The probable alteration of KLF-15 expres-
sion in girls with PCOS might mediate the obesity, hepatic 
steatosis and hyperandrogenism. Women with PCOS are 
also reported to have increased abdominal fat volume and 
insulin resistance independent from BMI [22]. In the pre-
sent study, BMI and waist circumference were significantly 
higher in the Phenotype A group in comparison to the 
other phenotypes. Therefore, it is not surprising that the 
incidence of MS was highest in the Phenotype A group. In 
addition, high TG levels in the Phenotype A group might 
also be explained by central obesity and increased visceral 
adiposity. As a component of MS, in our study group, the 
most common dyslipidemia in adolescents were the low 
HDL levels (HDL < 50). More than half of the patients had 
low HDL-C levels, and the levels did not differ between the 
four phenotypes. Fruzetti et al. also confirmed our results 
in Italian adolescent PCOS patients [19]. In contrast, a mul-
ticenter study reported that low HDL-C levels were more 
common in hyperandrogenemic adult women with PCOS 
as compared to normoandrogenemic women with PCOS 
(40.9% vs. 18.1%; p = 0,001) [23]. However, a recent study 
of 624 postmenopausal women found that endogenous 
androgen levels did not predict dyslipidemia, whereas 
HOMA-IR independently predicted HDL-C [24]. As a result, 
insulin resistance is a common feature of PCOS, and this 
might explain why all phenotypes had similar HDL levels.
Increased body weight is accepted as a major risk fac-
tor for MS. Increased body mass and androgen levels were 
also known to be related to inflammatory response, and 
proinflammatory cytokine production like TNF-α also con-
tributes to development of insulin resistance and metabolic 
syndrome in PCOS [18–25]. In accordance to literature, more 
than half of the Turkish PCOS adolescents were overweight 
in the present study. However, there are contradictory results 
about the prevalence of MS in normal-weight PCOS adoles-
cents. Some authors have proposed that the metabolic pro-
file of normal-weight PCOS adolescents was similar to that 
of the controls [26, 27]. In the present study, the incidence 
of MS in normal-weight Turkish adolescents was 6.1%; that 
increased to 25.5% in overweight adolescents and 67.7% in 
obese adolescents. As expected, BMI and waist circumfer-
ence were significantly higher in the PCOS adolescents with 
MS in comparison to those without MS.
Pathogenesis of metabolic syndrome is primarily related 
to insulin resistance, systemic inflammation and endothelial 
dysfunction. Metabolic syndrome and PCOS share common 
feature of insulin resistance. Recent data favors that intrao-
varian adrogen excess is the main defect in the majority 
of PCOS that leads to anovulation, polycystic ovaries and 
hirsutism. Insulin resistance might also increase androgen 
production from theca cells in response to LH and increase 
adipogenesis. The hyperandrogenemia itself also causes sec-
ondary LH elevation and aggravates the steroid dysfunction 
in PCOS. Therefore, this vicious cycle between insulin and 
androgen might be speculated to be the underlying cause 
of metabolic syndrome in PCOS. In the present study, the 
PCOS adolescents with MS were also found to have higher 
testosterone levels than those without MS. Similarly, Coviello 
et al. demonstrated that girls with PCOS had an increased risk 
of MS associated with increasing concentrations of unbound 
testosterone levels [13]. Fruzetti et al. showed that PCOS 
phenotypes with hyperandrogenemia had a more severe 
lipid profile than those with normal androgen levels [19]. 
 However, in the present study, adolescents with the nor-
moandrogenemic phenotype (Phenotype D) also had a rela-
tively high (15.2%) incidence of MS. 
The major strength of this study is that, it is one of 
the few studies that investigated the incidence of MS in 
four PCOS phenotypes diagnosed with Rotterdam crite-
ria. In addition, the endocrinologic and metabolic profiles 
of these phenotypes were compared in detail. However, 
this study also has some limitations. First, because this is 
a single center study the results cannot be generalized to 
the entire adolescent population with PCOS. That would 
require multicenter studies conducted on different ethnic 
groups. Second, because this is a cross-sectional study, we 
could not comment on whether or not the insulin resistance 
or metabolic profile of the adolescent participants changes 
over time or continues until adulthood. Third, because each 
group of PCOS phenotypes has relatively small number of 
patients, we could not make comparison of lean and obese 
adolescents in each group.
One in four adolescents with PCOS in our population has 
MS. The incidence of MS is highest among Turkish adoles-
cents with Phenotype A, where all of the Rotterdam criteria 
were fulfilled, and the incidence is lowest in Phenotype D, 
which is the normoandrogenemic phenotype. Regardless 
of the phenotype, the most common form of dyslipidemia 
in Turkish adolescents with PCOS is low HDL levels, and 
one in two has low HDL levels. Obesity and biochemical 
hyperandrogenism worsen MS in Turkish adolescents with 
PCOS. In order to evaluate the present risk factors and fur-
ther development of metabolic syndrome in adolescents 
with PCOS, follow-up studies should be done.
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